Drug Trial Radar · NCT01996306
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Last checked: Nov 19, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
650
Actual
Start
Dec 2, 2013
Primary completion
Nov 20, 2017
Study completion Jun 30, 2018
Sponsor
- Lead sponsor
- Epidemiological and Clinical Research Information NetworkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.
Conditions
- Colorectal Neoplasms
- Neoplasm Metastasis
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
Interventions
BevacizumabBiological
5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
CPT-11 (Irinotecan)Drug
150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
5-FU BolusDrug
400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
5-FU InfusionDrug
2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
l-LV (dl-LV)Drug
200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
bevacizumabBiological
7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
CPT-11 (Irinotecan)Drug
150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
CapecitabineDrug
1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: Assessed until 1.5 years after the last patient enrolment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NPO Epidemiological and Clinical Research Information Network (ECRIN)
Kyoto, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.